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occlusion was ﬁnally documented by coronary angiography.
RESULTS All patients were symptomatic (NYHA class 3 or 4). The target
septal vessels were successfully occluded in all patients, without com-
plications. The embolized septal branches: 1 vessel in 8 patients; 2 vessels
in 5 patients. The number of coils delivered ranged from 1to 3 / patient.
Moderate pain was recorded during and after the procedure and the cTnI
level increased four- to nine-fold. The pressure gradient diminished
during the procedure from 82  2.3 mm Hg to 27 15 mm Hg. Trans-
thoracic echocardiography showed a signiﬁcant reduction of the inter-
ventricular septum thickness and left ventricular outﬂow tract gradient
(23  3 vs. 15 2 mm, P ¼ 0.0001; 79  2.3 to 33  14mmHg, P ¼0.0001,
respectively) at 6 month-follow-up. Clinical improvement was recorded
in all patients compared with baseline (NYHA class 1 or 2), and all patients
were neither detected severe ventricular arrhythmia nor permanent
atrioventricular blockage following the procedure.Three patients pre-
sented permanent bundle branch block.
CONCLUSIONS Percutaneous transluminal coil embolization is an efﬁ-
cient and safe approach for transcatheter ablation of septal hypertrophy in
HOCM. This technique induced myocardial necrosis without the toxic
effects of alcohol septal ablation and surgical myocardial septal reduction.
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OBJECTIVES From the pedigrees of families with or without muta-
tions in beta-myosin heavy chain gene (MYH7) afﬂicted in two or more
generations with hypertrophic cardiomyopathy (HCM), age and
maximal wall thickness (MWT) of left ventricle at diagnoses were
evaluated to investigate the patterns of inheritance.
METHODS 56 individuals were analyzed from 25 families. Linear
mixed effects models were adopted to prevent misinterpretation due
to the cohort effect. Publication data contain 9 sarcomere mutations
(181 individuals in 52 families) were also extracted.
RESULTS MYH7 mutations were detected in 9 of the 25 probands, The
median age of HCM diagnosis was 24 in younger generation and 55 in
older (p < 0.001). In the parametric model, the estimated change in the
expected age at diagnosis for the entire cohort was 25.8 years (p < 0.001).
Statistically signiﬁcant earlier ages at diagnosis were also observed within
subgroups of MYH7þ and MYH7- mutations, proband over and below 30
years old families. Although the estimated change in MWT at diagnosis
for the entire cohort was only 2.161 mm (p ¼ 0.212), proband below 30
years subgroup got 10.393 mm (p ¼ 0.018) thicker in younger generation
in MWT, and showed a signiﬁcant reversed correlation with age. Analysis
of publication data also supports above ﬁnding.
CONCLUSIONS Familial HCM prone to be diagnosed at an earlier age in
later generations. Patients who are younger with relative contract to HCM,
especially those who be diagnosed earlier than 30 should continue to be
tracked to offer appropriate screening modalities as earlier as possible.
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OBJECTIVES To investigate the effect and safety of recombinant
human brain natriuretic peptide(rhBNP) on heart failure in acute se-
vere viral myocarditis patients(ASVMC).
METHODS 27 patients from Jan 2010 to Dec 2013 admitted to the Third
Afﬁliated Hospital of Sun Yat-Sen University were divided into two
group, rhBNP group 14 patients, control group 13 patients, rhBNP
group received rhBNP on the treatment of cedilanid, diuresis, vascular
dilation, BNP, cTnI, CK-MB and echocardiography were observed,
therapeutic effect of two group were also observed.
RESULTS rhBNP decreased BNP [(203.139.8)vs.( 1185.548.3) pg/
ml], cTnT [(13.59.8)vs. (24.813.2) mg/L], CK-MB[(32.910.7)
vs.(195.348.2) U/L], improved LVEF [(59.29.2)% vs.( 38.18.8)%]
signiﬁcantly, P<0.05. Furthermore, the therapeutic effect of rhBNP
group were better than control group (92.8% vs.84.6%, P<0.05), and
we didn’t observe obvious side effects in rhBNP group.CONCLUSIONS rhBNP is an effective and safe therapeutic measures
for heart failure in ASVMC.
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OBJECTIVES To review the clinical features of fulminant myocartitis,
in order to provide assistance to the clinical management.
METHODS The clinic data of 183 patients with viral myocarditis,
including 153 cases of acute myocarditis and 30 cases of fulminant
myocarditis admitted in our hospital during January 2008 and Dec
2012 were retrospectively analyzed. The age of onset, interval after
virus infect, initial symptoms, auxiliary examination, treatment, and
turnover were compared in the study.
RESULTS The average onset age of fulminant myocarditis and acute
myocarditis were similar[(22.37.6) vs(26.212.6) years, P¼0.1055]. There
was a signiﬁcant difference between the two gourps in the rate of patients
with a explicit history of virus infection[30.0%(9/30)vs 78.4%(120/153),
c2¼28.3, P<0.001], the average interval after virus infect [(3.12.2)
vs(7.03.80) d, P<0.001] and the length of hospital stay[(12.16.9)
vs(6.94.50) d, P<0.001]. Chest congestion (101/153,66.0%), feeble-
ness(76/153,49.7%), ﬂuster(74/153,48.4%) are the most onset symptoms of
acute myocarditis, while chest congestion (24/30,80.0%), shortness of
breath(14/30,46.7%), feebleness(13/30,43.3%) in ﬂunimant myocarditis.
Advanced A-V block(19/30,63.3%), cardiogenic shock(18/30 ,60.0%), ven-
tricular arrhythmia(16/30,53.3%), Adams-Stokes syndrome(8/30,26.67%)
and acute renal failure(8/30,26.7%) were the most complications of ﬂu-
nimant myocarditis. Temporary pacemaker(11 cases), extracorporeal
membrane exygenator(7 cases) and intra-aortic balloon pump(7 cases)
were applied in critical patients. In acute phase, 21 cases were cured, 9
cases was dead of cardiogenic shock and ventricular(27,30.0%). Two dead
cases applied with ECMO because of delay. These dead cases were died
within one week after be in hospital. Low ventricular ejection
fraction(P¼0.032), cardiogenic shock(P¼0.004), and mechanical ven-
tilation(P¼0.001) were relatived with dead of fulminant myocarditis in
acute phase. Three cases with low left ventricular ejection
fraction(EF<50%) who reviewed the echocardiography was normal one
month later. Besides 11 cases with ST-T wave imitated myocardiac
infarction was normal one month later. In follow-up of 21 cases fulminant
myocarditis, their heart functions were recovered(NYHA I), and 2 cases
relapsed, while 2 cases relapsed in the follow-up of 50 cases of acute
myocarditis. The relapsed cases all diagnosed with acute myocarditis, and
cured by nutritional supportive therapy. There is no signiﬁcant difference
between 2 groups(P¼0.357).
CONCLUSIONS The fulminant myocarditis has a rapid onset, most of
which has no prodrome of virus infection or a shorter interval than acute
myocarditis. Timely and effectivemechanical circulatory support is critical
for fulminant myocarditis. The prognosis of fulminant myocarditis is
favorable, and these is no difference compared with acute myocarditis.
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OBJECTIVES To explore the echocardiographic feature and prognosis
of cardiac amyloidosis due to multiple myeloma.
METHODS Patients with cardiac involvement of light-chain type
amyloidosis due to multiple myeloma conﬁrmed by pathology were
enrolled and echocardiographic data were analyzed retrospectively.
RESULTS Seven patients were identiﬁed (ﬁve man and two woman) be-
tween 1998 and 2015. Mean age at diagnosis was 53.19 5. 9 (49-59) years.
All patients presented cardiac manifestations (heart failure n¼6, rhythm
disorders n¼1) and extra-cardiac manifestations (renal n¼6, gastrointes-
tinal n¼5). Echocardiography demonstrated: Symmetrically increased LV
wall thickness in seven patients, one with normal size of LV cavity and six
with small LV cavity. Five patients showed small pericardial effusions.
Five patients with granular speckled appearance and two patients with
diffuse sparkling appearance．E/A ¼ 0.710.22, EF ¼ 52.116.2%. All pa-
tients with cardiac failure at diagnosis (n¼6) died with a median survival
of 1.5 month duration.
CONCLUSIONS Cardiac involvement is rare but crucial in patients’
prognosis with multiple myeloma. The typical echocardiographic ap-
pearances would be enough to diagnose cardiac amyloidosis, if an addi-
tional histological specimen from another tissue conﬁrms amyloidosis.
